# Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

> **NCT02340780** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 14 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Buparlisib

## Key facts

- **NCT ID:** NCT02340780
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-27
- **Primary completion:** 2018-11-21
- **Final completion:** 2020-04-28
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340780, "Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02340780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*